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Abstract
Matrix metalloproteinases (MMPs) play critical roles in cancer invasion and
metastasis by digesting basement membrane and extracellular matrix (ECM). Much
attention has focused on the enzymatic activities of MMPs; however, the regulatory
mechanism of MMP expression remains elusive. By employing bioinformatics analysis,
we identified a potential p53 response element within the MMP-14 promoter.
Experimentally, we found that p53 can repress MMP-14 promoter activity, whereas
deletion of this p53 response element abrogated this effect. Furthermore, we found
that p53 expression decreases MMP-14 mRNA and protein levels and attenuates
MMP-14-mediated cellular functions. Additional promoter analysis and chromatin
immunoprecipitation studies identified a mechanism of regulation of MMP-14
expression by which p53 and transcription factor Sp1 competitively bind to the
promoter. As the correlation between inflammation and cancer aggressiveness is well
described, we next sought to evaluate if inflammatory cytokines could differentially
affect p53 and MMP-14 levels. We demonstrate that interleukin-6 (IL-6) downregulates p53 protein levels and thus results in a concomitant increase in MMP-14
expression, leading to enhanced cancer cell invasion and metastasis. Our data
collectively indicate a novel mechanism of regulation of MMP-14 by a cascade of
IL-6 and p53, demonstrating that the tumor microenvironment directly stimulates
molecular changes in cancer cells to drive an invasive phenotype.

Introduction

growth and aggression, the mechanisms by which MMP14 are regulated remain poorly described. Transcription
factors Egr-1 and Hif-2α as well as miRNA-181 have been
found to be involved in regulation of MMP-14 expression
[9–11]. Perhaps most notably though, regulation by
transcription factor Sp1 has been identified by several
groups as the primary factor regulating expression of the
MMP-14 gene [12, 13]. In normal, non-cancerous adult
tissue, Sp1 levels typically remain constant and do not
fluctuate [14]. Despite this, MMP-14 levels are generally
repressed. If Sp1 is indeed the primary transcription factor
responsible for MMP-14 expression, other regulatory
molecules must then have a critical role to keep MMP-14
levels in check when the body is in homeostasis.
While MMP-14 expression in human oral cancer
specimens has been demonstrated by immunohistochemistry

Matrix metalloproteinases (MMPs) comprise a
family of approximately 25 zinc-dependent endopeptidases.
While originally believed to primarily serve to remodel the
extracellular matrix (ECM), MMPs are now understood
to have a wide variety of substrates and functions,
including activation of bioactive signaling molecules
or other proteases and participating in transduction of
cellular signaling pathways [1, 2]. MMP-14, also known
as membrane type-1 MMP (MT1-MMP), is a membrane
bound MMP overexpressed in most cancer cells which is
correlated to poor patient prognosis [2, 3]. MMP-14 has
also been demonstrated to promote cell migration and
invasion [3, 4], angiogenesis [5, 6], and metastasis [7, 8].
Despite the prominent role of MMP-14 in driving cancer
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(IHC) to occur in the absence of p53 [15] and several
studies have demonstrated that p53 status directly
correlates with the invasiveness of tumors [16, 17], a direct
or causative association between these proteins has yet to
be established. While approximately 50% of all cancers
have mutated p53, the gene for the so-called “guardian of
the genome” remains unaffected in the other half. Despite
retention of the wild type alleles, these cancers can still
grow, degrade the basement membrane, and metastasize.
It has recently been demonstrated that cytokine signaling
via signal transduction protein gp130 in inflamed tumor
microenvironments can downregulate p53 protein levels
[18, 19]. Specifically, interleukin-6 (IL-6) and its closely
related cousin leukemia inhibitory factor (LIF) have
been implicated. Interleukin-6 is one of the most wellcharacterized pro-inflammatory cytokines found in tumors
and has been shown to drive tumor growth and proliferation
[20], stimulate angiogenesis [21], lead to chemoresistance
[22], promote epithelial-to-mesenchymal transition [23],
and increase the rate of metastasis [24]. It is estimated that
at least 20% of cancers occur as a direct result of infection
and chronic inflammation. Furthermore, the remaining 80%
of these cancers often come to be highly infiltrated with
inflammatory cells and exhibit high levels of cytokines
within the tumor microenvironment [25].
In this study, we identified that not only can p53
repress MMP-14 expression, but that interleukin-6
signaling can decrease p53 levels and cause a concomitant
increase in MMP-14 levels. We show that inflammatory
cytokine signaling increases degradation of p53 to
increase Sp1-mediated transcription of MMP-14. We
also demonstrate that interleukin-6 promotes MMP-14mediated invasion and metastasis using in vitro and in vivo
experimental models. Our data highlight a functional role
for interleukin-6 in cancer dissemination via MMP-14 and
pose a new rationale for therapeutically targeting the IL-6
signaling pathway in cancer.

analysis using corresponding antibodies (Figure 1A).
This observation led us to further characterize the effect
of p53 on regulation of MMP-14 expression. Human
fibrosarcoma HT1080 cells, which endogenously express
high levels of MMP-14, were employed to ectopically
overexpress p53. When p53-GFP chimeric cDNA was
transiently transfected into HT1080 cells, endogenous
MMP-14 expression was reduced as compared to
vector cDNA control (Figure 1B). To substantiate
these observations, we cloned the human MMP-14
promoter from the genomic DNA of HT1080 cells and
the promoter was placed at the 5′ end of a myc-tagged
MMP-14 construct consisting of the open reading frame
(named pMMP-14 ORF). When pMMP-14 ORF was cotransfected with p53 or vector control, p53 significantly
reduced MMP-14 expression (Figure 1C). In addition, this
demonstrates that transfection of wild-type p53 results in
reduction of MMP-14 expression, ruling out the artificial
effect by p53 and GFP fusion (Figure 1C). Both pro- and
active forms of MMP-14 (60 and 57 kD, respectively) can
be observed in our blots.
To determine if the regulation of MMP-14 by
p53 occurred at the transcriptional level, real-time RTPCR for the mRNA of MMP-14 in HCT-116 p53+/+ cells
versus HCT-116 p53−/− cells and HT-1080 cells transiently
overexpressing p53 or vector control was performed. Our
real-time RT-PCR data substantiates the Western blot data
and demonstrates that p53 expression is associated with
significantly decreased MMP-14 mRNA (Figure 1D).
To further determine whether reduced MMP-14
expression by p53 decreases functional MMP-14, we
employed a MMP-14 functional assay by monitoring
latent MMP-2 (proMMP-2) activation. proMMP-2 is
a secretory MMP in which the prodomain is partially
cleaved by functional MMP-14 to produce an intermediate
form (IntMMP-2) which then becomes fully activated
MMP-2 (ActMMP-2) [26]. The conditioned media from
HT-1080 cells overexpressing p53 or vector control were
examined by gelatin zymography. Consistent with the
protein expression level of MMP-14, ectopic expression
of p53 resulted in decreased proMMP-2 activation as
compared to vector control, whereas proMMP-9 is
unaffected (Figure 1E).
Because MMP-14 has been shown to increase cancer
cell migration independently of its catalytic function [27],
a two-dimensional cell migration assay was therefore
used to determine if the p53-mediated downregulation
of MMP-14 results in decreased migration of HT-1080
cells. As expected, cells overexpressing p53 migrated
significantly less than the control cells (Figure 1F). The
phenotypes observed are not due to differences in cell
viability caused by differences in p53 levels. In HT-1080
cells transient transfection of p53 did not induce apoptosis
within the time course of the experiments as evidenced
by apoptosis assay using Annexin V as a marker followed
by flow cytometry analysis (Supplementary Figure S1A).

Results
p53 downregulates MMP-14 expression and
functions
MMP-14 is frequently overexpressed in cancer and
has been shown to play a critical role in tumor growth
and metastasis. While several reports have suggested a
correlation between p53 status and MMP-14 expression
[15–17], a direct link between the two has not been
established. To determine the relationship between p53
and MMP-14 expression, we first surveyed a genetically
engineered strain of the human colon cancer cell line
HCT-116 in which the p53 gene was permanently knocked
out (HCT-116 p53-/-), and compared the results with wildtype HCT-116 (HCT-116 p53+/+) cells. Surprisingly, an
inverse correlation between p53 and MMP-14 expression
was observed when examined by Western blotting
www.impactjournals.com/oncotarget
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Figure 1: p53 expression is inversely correlated with MMP-14 levels. (A) Western blotting was performed in p53 wild-type

(p53+/+) and p53 null (p53−/−) HCT-116 cells using anti-p53 and anti-MMP-14 antibodies. β-actin was used as a loading control. MMP-14
was only detected in p53−/− HCT-116 cells, but not in p53+/+ HCT116 cells. (B) Ectopic expression of p53-GFP in HT-1080 cells results
in a decrease of MMP-14 levels as demonstrated by Western blotting analysis using anti-p53, anti-MMP-14 antibodies. β-actin was used
as a loading control. (C) Co-expression of MMP-14 cDNA encoding the open reading frame of MMP-14 driven by its native promoter
(pMMP-14 ORF) with p53 cDNA leads to decreased MMP-14 expression compared to vector control when examined by a Western blotting
using corresponding antibodies. β-actin was used as a loading control. (D) Total RNA extracted from HT-1080 cells transfected with p53
or control cDNA and p53+/+ and p53–/– HCT-116 cells was examined by real time RT-PCR using MMP-14 primers. HPRT-1 was used as
a normalization control. An inverse correlation between p53 expression and MMP-14 levels was observed in gene transcriptional levels.
(E) Gelatin zymography was employed to examine functional MMP-14 in terms of proMMP-2 activation. Ectopic expression of p53 in
HT-1080 cells attenuates MMP-14-mediated proMMP-2 activation. proMMP-2: latent form of MMP-2; IntMMP-2: intermediate form
of MMP-2; and act MMP-2: fully activated MMP-2. (F) Dot migration assay was conducted to examine the effect of p53 on cancer cell
migration. HT1080 cells transfected with vector control and p53 cDNA were mixed with collagen type I and dotted onto a 96-well plate.
After a 24 hours incubation, the cells were fixed and stained with DAPI for nuclear staining (right panel) followed by microscopic counting
of migrated cells (left panel). *p < 0.05, **p < 0.01, ***p < 0.001.
www.impactjournals.com/oncotarget

61109

Oncotarget

Similarly, loss of the p53 gene did not significantly affect
cell viability in HCT-116 cells as measured using the
MTT viability assay (Supplementary Figure S1B). Our
data suggest that wild-type p53 affects MMP-14 gene
expression leading to reduced function of MMP-14.

p53 regulation (Figure 3A and 3B). Interestingly, this
p53 response element is partially overlapped with a
predicted Sp1 binding site, suggesting p53 and Sp1 could
competitively bind to the MMP-14 promoter (Figure 3A).
Sp1 has been previously reported to positively
regulate MMP-14 expression [13, 30, 31]. Separately,
studies have demonstrated that p53 can bind to promoters
to repress Sp1-mediated transcription by blocking access
of this transcription factor to the promoter [32–34]. To
examine if p53 and Sp1 competitively bind to the MMP-14
promoter at -nt66 to -nt59, we performed chromatin
immunoprecipitation (ChIP) coupled with quantitative
real-time PCR to study p53 and Sp1 binding to the MMP-14
promoter. Notably, a significant amount of DNA is
precipitated by the p53 antibody at the p21 promoter
in p53 wild type cells only, while minimal or no DNA
is precipitated from the p53 null cells or by the Sp1
antibody, validating our ChIP system (Supplementary
Figure S2A). Additional validation demonstrated that
minimal DNA is precipitated by either p53 or Sp1
antibodies from the MMP-14 promoter in a region outside
the predicted binding sites, as expected (Supplementary
Figure S2B). In the HCT-116 cells that express wild type
p53, DNA at the MMP-14 promoter was precipitated with
the p53 antibody but not in the p53 null HCT-116 cells
(Figure 3C). However, in the p53 null cells, the amount
of DNA at the MMP-14 promoter precipitated by the
Sp1 antibody displayed 3 times more compared to that
precipitated from the p53 wild type cells (Figure 3D).
Importantly, no significant differences are observed
in Sp1 levels after over-expression of wild type p53 in
HT-1080 cells or loss of the p53 gene in HCT-116 cells
(Supplementary Figure S3).

p53 represses MMP-14 promoter activity
To dissect the molecular mechanism underlying p53regulated MMP-14 expression, we characterized the effect
of p53 on MMP-14 promoter activity. A bioinformatics
approach employing two different promoter-prediction
programs (Genomatix Model Inspector and PromoterPrediction Server at Duke University) was conducted to
identify the promoter region of MMP-14. We subsequently
utilized PCR amplification of the promoter using genomic
DNA derived from HT1080 cells as a template. A 1.2 kb
fragment of the deduced promoter including the first exon
was amplified and cloned into a pGL3-basic vector lacking
a promoter and including the firefly luciferase reporter
gene. Since p53-mediated reduction of MMP-14 promoter
activity may be through a direct or an indirect effect on
the MMP-14 promoter, 5′ deletion analysis was conducted.
Parts of the MMP-14 promoter were sequentially deleted
starting from the 5′-end to generate 3 different deletion
mutants of different lengths (Figure 2A). The deletion
constructs were co-transfected with p53 or vector control
into COS-1 cells followed by the Dual Luciferase assay.
p53 represses all 3 deletion mutants similar to full-length
MMP-14 promoter as compared to vector control
(Figure 2B), suggesting that the response element of p53
within the MMP-14 promoter may lie within the 500
bp region of the promoter immediately upstream of the
transcription start site (+1). To further narrow down the
region containing the p53 response element, sequential
deletions of approximately fifty base pairs starting at the
5′-end of the 0.5 kb MMP-14 promoter were generated
(Figure 2C). As evidenced by the results of the luciferase
assay, only deletion of region seven (D7, nt −94 to nt
−44) abolished the ability of p53 to negatively affect the
promoter activity compared to the control (Figure 2D).

Interleukin-6 decreases p53 and causes a
concomitant increase in MMP-14 expression to
increase metastases and metastatic growth in vivo
Inflammation is an important hallmark of cancer,
known to drive cancer progression and aggression. It
has recently been demonstrated that interleukin-6 (IL-6)
can downregulate p53 protein levels [18]. To explore a
potential cascade of IL-6 and p53 in driving MMP-14
expression, we initially obtained cytokines, which include
IL-6, released from the human monocytic precursor cell
line U937. Using a two-step induction process of U937
cells sequentially treated with PMA and LPS, IL-6
is released from differentiated monocytes or mature
macrophages by LPS [35, 36]. The conditioned medium
containing IL-6 was then incubated with both HCT-116
and HT-1080 cells followed by Western blotting analysis.
The conditioned media from U937 macrophages doubled
the levels of MMP-14 in both cells lines. Stimulation of
the U937 cells, however, with LPS led to a 50% decrease
in p53 levels (Figure 4A, Supplementary Figure S4).

p53 regulates MMP-14 promoter activity by
competitively interacting with the transcription
factor Sp1 at the MMP-14 promoter
Using the bioinformatics analysis tool PROMO as
previously described [28, 29], we identified 3 potential
p53 response elements within the MMP-14 promoter:
-nt1137 to -nt1130, -nt74 to -nt68, and -nt66 to -nt59. The
first p53 response element was in the antisense orientation;
however, this region was already ruled out as required for
p53-mediated regulation of MMP-14 (refer to Figure 2A).
When the second and third deduced p53 response elements
were individually mutated, only the third predicted
response element, -nt66 to -nt59 failed to respond to
www.impactjournals.com/oncotarget
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Since the conditioned medium collected from the
mature macrophages contains cytokines in addition to
IL-6, we next treated the cells using pure recombinant IL-6
protein in order to determine the role of IL-6 in regulation
of p53 and MMP-14. HT1080 cells were treated with
recombinant IL-6 followed by Western blotting analyses
for p53 and MMP-14 using corresponding antibodies.
Treatment of HT1080 cells with IL-6 decreased p53
protein levels leading to increased MMP-14 expression

(Figure 4B, left panel). In agreement with the observation
from HT1080 cells, treatment of wild-type HCT116 with
recombinant IL-6 also resulted in decreased p53 and
increased MMP-14 (Figure 4B, right panel). These results
indicate that MMP-14 is regulated through IL-6-p53
cascade.
We next examined if upregulated MMP-14 by IL-6
contributes to promoting cancer dissemination. Given the
limitation of the in vivo model system for constant presence

Figure 2: Identification of p53 response element with the MMP-14 promoter. (A) A schematic diagram of the full length
and truncated MMP-14 promoters termed truncation A through D. (B) Co-transfection of p53 cDNA with pMMP-14-Luc demonstrates
by luciferase assay that p53 decreases MMP-14 promoter induction. As the shortest truncation, truncation D, also has decreased promoter
induction by p53 compared to vector control, region D is determined to contain the p53 regulatory response element. Renilla luciferase
was used as a normalization control. (C) A schematic diagram of deletion mutants of approximately 50 bp within the region D. (D) Coexpression of p53 cDNA with pMMP-14-Luc at deletion 7 no longer attenuates promoter induction compared to vector control, indicating
D7 contains the p53 regulatory response element. Renilla luciferase was used as a normalization control. ***p < 0.001.
www.impactjournals.com/oncotarget
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Interleukin-6 decreases p53 expression by
increasing its degradation

of localized IL-6, an experimental metastasis model was
chosen in which HT1080 cells were treated with IL-6 or
vehicle control and then injected via tail vein. We first
generated stable HT1080 cells expressing GFP to facilitate
visualization of lung metastatic tumor colonization. After
10 days post-injection of the cells pre-treated with IL-6
or vehicle control for 24 hours, animals were sacrificed
and the lungs were microscopically examined for tumor
nodules based on GFP marker and hematoxylin and eosin
(H&E) staining. The lungs of animals injected with the IL6-treated cells were better colonized by tumor cells and
had more fibrotic lesions compared to the lungs of animals
receiving vehicle-treated cells (Figure 4C). Analysis of
the gross tissue shows increased GFP-positive colonies,
representing metastases to the lungs. Furthermore, IL-6
treatment significantly increased both the number and size
of the metastases present on the lungs compared to vehicle
control (Figure 4D and 4E). Our study collectively suggests
that MMP-14 is negatively regulated by wild-type p53, and
MMP-14 is upregulated in the tumor microenvironment as
a result of IL-6-mediated suppression of p53 levels.

IL-6 has been reported to regulate p53 protein
levels [22]. However, the regulatory mechanism remains
elusive. We next sought to determine the mechanism by
which IL-6 downregulates p53. It is known that p53 is
mainly regulated post-translationally [37]. As anticipated,
treatment of cells with IL-6 did not significantly decrease
p53 mRNA levels in both HT1080 and HCT116 p53+/+
cells, suggesting IL-6 regulates p53 post-translationally
(Figure 5A). To test this possibility, HT-1080 cells and
HCT-116 p53+/+ cells were treated with a protein synthesis
inhibitor, cycloheximide, or a proteasome inhibitor,
MG-132, before IL-6 or vehicle control treatment. While
treatment of both cell lines with cycloheximide had no
effect on the decrease of p53 caused by IL-6, MG-132
abolished the effect of IL-6 on downregulation of p53
protein level in both cell lines (Figure 5B). Together, this
suggests that IL-6 exerts its effect on p53 expression by
increasing proteasomal degradation of p53.

Figure 3: p53 and Sp1 bind competitively at the MMP-14 promoter. (A) Bioinformatic analysis identifies two potential p53

binding sites within deletion 7, the second of which is also a predicted Sp1 binding site. (B) Reporter gene assay was performed in COS-1
cells co-transfected with MMP-14 reporters for truncation D, D7, and mutated p53 or p53/Sp1 response elements (termed p53mut or p53/
Sp1mut, respectively) along with either vector control or wild type p53 cDNAs followed by a luciferase assay. Renilla luciferase was used
as a normalization control. Mutation at the second p53 binding element no longer responds to p53 expression. (C) ChIP-qPCR assay was
performed using a p53 antibody to precipitate DNA from p53 wild-type (p53+/+) and p53 null (p53−/−) HCT-116 cells. Real time RT-PCR
was then conducted using primers specific for MMP-14 promoter. MMP-14 promoter is precipitated by p53 antibody in HCT-116 (p53+/+)
cells, whereas none is precipitated in p53−/− cells. (D) ChIP-qPCR was performed in HCT-116 cells with wild type or null p53 expression
using anti-Sp1 antibody followed by a real time RT-PCR for MMP-14 promoter region. IgG and input samples were used as normalization
controls. Results are expressed as percent of input. ***p < 0.001.
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Because MDM2 is the known E3 ubiquitin ligase
for p53, we next examined MDM2 levels after treatment
with IL-6. Western blotting analyses demonstrate that IL-6
treatment increases MDM2 expression in both HT-1080
and HCT-116 cells (Figure 5C and 5D), supporting our
hypothesis that IL-6 leads to p53 degradation via MDM2.
We then sought to decipher the signaling pathway by
which IL-6 leads to increased MDM2 and thus decreased
p53 levels. The classical signaling pathway through
which IL-6 functions is via binding to the gp130 Janus
associated kinase (gp130-JAK) receptor and stimulating
phosphorylation of Stat3. p-Stat3 then translocates to
the nucleus where it acts as a transcription factor [38].
Treatment of both HCT-116 cells (Figure 6A) and HT-1080
cells (Figure 6B) with the phospho-Stat3 inhibitor BP-1-

102 prior to IL-6 treatment attenuated the IL-6-mediated
increase in MDM2 levels and thus abrogated the ability of
IL-6 to decrease p53 levels (refer to Figure 5C and 5D).
IL-6 is also known to be capable of activating the
MAP-kinase pathway and the PI3k/AKT pathway. HCT116 and HT-1080 cells were serum-starved and then
pre-treated with either LY294002, a PI3K inhibitor, or
U0126, a MEK inhibitor, followed by treatment with
IL-6. In HCT-116 cells (Figure 5C), treatment of IL-6
increased phosphorylation of AKT, an effector molecule
of the PI3K pathway. Inhibition of AKT activity abrogated
the downregulation of p53, an expected result given
that phosphorylation of MDM2 by AKT is required in
order for MDM2 to translocate to the nucleus where it
degrades p53 (Figure 6A). Surprisingly, inhibition of

Figure 4: Interleukin-6 decreases p53 levels, leading to a concomitant increase in MMP-14 expression in HT-1080
and HCT-116 WT cells and drives metastasis and growth of HT-1080 cancer cells in vivo. (A) Western blotting analysis

was performed on HT-1080 and HCT-116 p53 wild type (WT) cells in the presence of LPS or with conditioned media (CM) from U937
macrophage cells that were activated with LPS to induce cytokine secretion or with water as vehicle control for 24 hours. While CM from
U937 cells increase MMP-14 levels, only after macrophage activation was a decrease in p53 observed using anti-p53 and anti-MMP-14
antibodies. β-actin was used as a loading control. (B) Western blotting analysis was performed on HT-1080 and HCT-116 cells treated with
50 ng/mL recombinant IL-6 or 1% BSA vehicle control for 24 hours followed by Western blotting. A decrease in p53 was observed along
with a concomitant increase in endogenous MMP-14 using the corresponding antibodies. β-actin was used as a loading control. (C) H&E
staining of paraffin-embedded sectioned lung tissue sections (top panel) and the presence of GFP lesions on the gross lung tissue (bottom
panel) indicates increased formation of metastases. The number (D) and size (E) of GFP-positive lesions per image are significantly
increased in mice which received IL-6-treated cells (n = 9) compared to control (n = 10). Lesion size was determined using Nikon Imaging
Software. ***p < 0.001.
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PI3K phosphorylation also abrogated the effect of IL-6 on
total MDM2 levels. This suggests a previously unknown
mechanism of regulation of MDM2 expression in
HCT-116 cells. Interestingly, we also found that inhibition

of phospho-Stat3 blocks phosphorylation of AKT
(Supplementary Figure S5), suggesting that the activation
of phospho-AKT is downstream of phospho-Stat3 and not
necessarily independent of it. In HT-1080 cells (Figure 5D),

Figure 5: The decrease of p53 by IL-6 is due to increased rate of degradation by E3 ubiquitin ligase MDM2 via cellspecific signaling pathways. (A) p53 mRNA levels normalized to HPRT-1 were analyzed by real time RT-PCR. p53 mRNA levels do

not significantly change in either HT-1080 or HCT-116 cells after stimulation with IL-6. (B) Western blotting of HT-1080 and HCT-116
cells using an anti-p53 antibody demonstrates that inhibition of protein synthesis by 20 ug/mL cycloheximide (CHX) in both cells lines has
no effect on the decrease in p53 protein stimulated by IL-6. However inhibition of proteasomal degradation by 10 uM MG-132 completely
blocks downregulation of p53 and stabilizes p53 protein levels, indicating IL-6 regulates p53 levels by increasing its degradation. β-actin
was used as a loading control.(C) In HCT-116 cells, IL-6 stimulation activates p-Stat3 and p-AKT pathways compared to vehicle control.
Furthermore, MDM2 levels are increased whereas p53 levels are decreased as evidenced by western blotting using the corresponding
antibodies. The MAP-K pathway is not activated by IL-6, as evidenced by the lack of ERK 1/2 phosphorylation in response to IL-6.
(D) In HT-1080 cells were treated as in C and analyzed by Western blotting. In this cell line, the p-Stat3 pathway only is activated, leading
to increased MDM2 levels and decreased p53 levels.
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Discussion

phosphorylation of AKT was not increased by IL-6,
although similar to HCT-116 cells inhibiting p-AKT
did abrogate the IL-6-mediated downregulation of p53
as expected without affecting IL-6 upregulation of total
MDM2 levels (Figure 6B). Neither cell line demonstrated
any activation of p-ERK nor was IL-6-mediated
downregulation of p53 or upregulation of MDM2 affected
by inhibition of this pathway (Figure 5C and Figure 5D).
We therefore conclude that the MAP-kinase pathway does
not contribute to IL-6 regulation of p53 in these cell lines.

In this study, we demonstrate for the first time a role
for the tumor suppressor p53 in down-regulating MMP-14
expression. We then demonstrate that p53 regulates MMP14 expression at the transcriptional level by binding to the
promoter region and competitively blocking binding of the
known MMP-14 transcription factor Sp1. We also identify
the mechanisms by which IL-6 can increase the rate of
proteasomal degradation of p53, allowing for the Sp1

Figure 6: Inhibition of signaling pathways identifies key mediators of the IL-6-driven decrease in p53 in a cell-specific
manner. (A) In HCT-116 cells, treatment with p-Stat3 inhibitor BP-1-102 at 5 ug/mL abrogates the down-regulation of p53 by IL-6 as well

as the increase in MDM2. Successful inhibition of PI3K, as observed via lack of phosphorylation of effector AKT, using 20 uM LY294002
abrogates IL-6-downregulation of p53 as well as the increase in MDM2. Inhibition of MEK, as observed via lack of phosphorylation of
effector molecules ERK 1/2, with 20 uM U0126 has no effect on IL-6-driven regulation of p53 or MDM2, as expected. β-actin was used as
a loading control. (B) Treatment of HT-1080 with BP-1-102 abrogates the down-regulation of p53 by IL-6 as well as the increase in MDM2.
Neither treatment with LY294002 or U0126 in these cell lines upsets the effects of IL-6 on MDM2 levels, as expected. U0126 does not
affect IL-6 downregulation of p53. However, due to the effects of LY294002 on blocking nuclear transport of MDM2 the p53 levels do not
decrease in response to IL-6 in this condition. β-actin was used as a loading control.
www.impactjournals.com/oncotarget

61115

Oncotarget

binding site to become exposed and thus MMP-14 levels
to increase (Figure 7). Importantly, our work shows that
IL-6 confers increased invasive and metastatic potential
even to cancer cells which are p53 wild type.
p53, although largely known for its transcriptional
capabilities, performs a multitude and diverse spectrum of
activities within cells. Not only can p53 bind to DNA in
a sequence specific manner to increase gene expression,
but it can also function to repress gene expression [39].
Three mechanisms of p53-mediated repression have been
proposed: (1) interference of the transcriptional complex
assembly on the promoter, (2) interference of assembly
of the basal transcriptional machinery itself which may
be DNA-independent, and (3) recruitment of chromatinmodifying factors to reduce promoter accessibility [39].
Our research identifies repression of MMP-14 expression
by p53 as belonging to the first category. While several
groups have demonstrated previously that the transcription
factor Sp1 regulates MMP-14 expression [9, 12], a
relationship of p53 to MMP-14 expression has never
before been clearly described. Analysis at the promoter
indicates that p53 competes for binding with Sp1, and
once bound sterically blocks Sp1 binding. It is therefore
of little surprise that nearly all cancer cell lines expressing
high levels of MMP-14 are either p53 low, p53 null, or
harbor a mutation in p53.
While IL-6 has previously been linked to decreased
p53 levels, the mechanism of how this regulation

occurs has not been thoroughly investigated. Herein,
we demonstrate that IL-6 activates via phosphorylation
transcription factor Stat3 which increases MDM2 levels.
Of note, our data also implicates a role for AKT in this
pathway but via a novel activation mechanism. Previous
work by others has concluded that IL-6 signaling can
lead to phosphorylation and activation of AKT via the
PI3k pathway [40]; however, our data demonstrates that
activation of AKT in HCT-116 cells can actually occur as
a result of Stat3 activation (Supplementary Figure S4).
Due to the fact that IL-6 does not activate AKT in HT1080 cells, it is likely that different cell lines or different
cancers may activate different pathways in response to
IL-6. This supposition is supported by the work of two
other groups who have investigated a mechanism by
which inflammation leads to downregulation of p53. Yu
et al. found that LIF, a member of the IL-6 family, also
leads to p53 downregulation via activation of Stat3 with a
subsequent increase in MDM2 levels [19], although they
did not investigate AKT in their study. Brighenti et al.
on the other hand convincingly describe a different
mechanism by which IL-6 signaling indirectly leads
to decreased p53 levels. In their model, IL-6 stimulates
ribosomal biogenesis, a Stat3-driven process which
results in increased amounts of MDM2 available for
binding p53 without increasing total MDM2 levels [41].
Furthermore, this work goes on to describe how IL-6driven downregulation of p53 induces phenotypic changes

Figure 7: Overview of the mechanism by which IL-6 downregulates p53, leading to increased MMP-14-expression.

IL-6 binds to its receptor which then forms a complex with GP130. This leads to activation of JAK kinase, which in turn activates STAT3
and AKT (via the PI3K pathway). Phosphorylation of STAT3 leads to translocation of this molecule to the nucleus where it serves as a
transcription factor and induces expression of E3 ubiquitin ligase MDM2. Similarly, IL-6-induced phosphorylation of AKT in HCT-116
(but not HT-1080) cells leads to increased expression of MDM2 levels. Furthermore, p-AKT induces the translocation of cytosolic MDM2
molecules to the nucleus. A primary target of MDM2 is p53; ubiquitination and subsequent degradation of p53 at the MMP-14 promoter
allows for transcription factor Sp1 to bind to the MMP-14 gene and increase its expression.
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Sigma-Aldrich; anti-phospho-AKT and anti-total AKT
antibodies were obtained from Cell Signaling. Anti-actin
antibodies were attained from Cell Signaling Technologies
and anti-IgG was obtained from Millipore for probing
loading or experimental setup controls, respectively.
Horseradish-peroxidase (HRP) conjugated anti-mouse
and anti-rabbit secondary antibodies were acquired from
Rockland Immunochemicals. Hoechst nuclear stain was
acquired from Invitrogen. Proteasome inhibitor MG-132
and protein synthesis inhibitor cycloheximide were acquired
from Sigma-Aldrich. Recombinant IL-6 was purchased
from either Sigma-Aldrich or Gold Biotechnology. STAT3
Inhibitor XVIII, BP-1-102 and PI3K inhibitor LY294002
were acquired from Calbiochem; MEK1/2 inhibitor U0126
was acquired from Cell Signaling Technologies.

in cells indicative of an epithelial-to-mesenchymal
transition. From this work done by us and others we can
extrapolate that inflammation can drive cancer progression
but the mechanism by which this occurs can vary.
The data presented herein not only provide a
plausible and convincing explanation for how IL-6
increases MMP-14 in cancer to drive metastasis, but
implications of this research can be extended into multiple
other fields of study. Indeed, pathological states in which
inflammation is correlated with increased MMP-14
expression include irritable bowel disease which causes
increased MMP-14 levels in the colonic mucosa [42],
inflammation resulting from cardiac myopathies causing
increased MMP-14 in myocardium [43], and atheromaassociated inflammation leading to increased levels of
MMP-14 in vascular epithelial cells [44]. In each of these
cases, the increase in MMP-14 correlates with remodeling
of the tissue and/or vasculature that can lead to increased
morbidity and rates of mortality. While MMP-14 is an
attractive therapeutic target, attempts at inhibiting MMPs
directly have failed spectacularly during clinical trials [45].
Establishing a causative link between inflammation and
MMP-14 expression thus opens the door for development
of therapeutics which may disrupt this signaling pathway.
Several monoclonal antibodies and small molecule
inhibitors of the IL-6 pathway have already been evaluated
clinically for a variety of inflammatory disorders,
with IL-6 receptor antagonist tocilizumab (Actemra,
Genentech), a recombinant humanized monoclonal
antibody, clinically approved for treatment of rheumatoid
arthritis. The data presented in this paper strongly support
the idea that IL-6 inhibitors may be of great benefit to
cancer patients. It is also worth noting that IL-6 signaling
in the tumor microenvironment is actually increased after
chemotherapy and directly contributes to chemoresistance.
IL-6 can turn on expression of multidrug resistance
protein 1 (mdr1) [46], allow cells to evade apoptosis
[22], and attenuate the antigen-presenting capabilities of
dendritic cells in the tumor microenvironment to repress
an immunogenic response [47]. As such, co-therapy of
an IL-6 pathway inhibitor with standard chemotherapy
should theoretically produce a synergistic response and
vastly improve patient outcomes.

Cell culture and transfection
All cell lines used in this study, except HCT-116
p53 −/−, were purchased from the American Type Culture
Collection (ATCC, Manassas, VA) and cultured as
recommended. The HCT-116 p53 −/− cell line was kindly
provided to us by Dr. Ute Moll (Stony Brook University,
NY, USA). HT-1080, HCT-116, and HCT-116 p53 −/−
cells were cultured in DMEM media containing 10% FBS
and in 5% CO2. U937 cells were cultured in RPMI1640
media containing 10% FBS and in 5% CO2. To achieve
transient transfection of cells, polyethyleneimine (MW:
250 K, Polysciences) was incubated with plasmid DNA
for 30 minutes at room temperature prior to addition to
cells. Medium was replaced after 18 hours and assays
were performed after the indicated recovery period.

Quantitative real-time PCR
RNA from cultured cells was isolated by Trizol and
reverse transcriptase (BioRad iScript cDNA Synthesis
Kit) was used to generate cDNA. Quantitative real-time
PCR was performed using BioRad iQ SYBR-Green Super
Mix on a BioRad iQ5 Real Time PCR machine. Relative
expression was calculated using the ΔΔCt method.
HPRT-1 was used as an internal control. Primers used for
detection can be found in Supplementary Table S1.

Dot-based cell migration assay

Materials and methods

HT-1080 cells were transiently transfected for 18
hours, embedded into a collagen matrix, and dotted in a
96-well plate. Solidified cell-matrix dots were overlaid
with complete media. Cells were allowed to migrate for
up to 8 hours, fixed, and then stained in Hoechst/PBS
(1:2000). Images were captured using the previously
described microscope and camera system and migration
was quantified by counting nuclei using the Nikon
Elements Basic Research Software analysis tools [48].

Materials
Anti-p53, anti-phospho-Stat-3 and total Stat-3
antibodies were acquired from Santa Cruz Biotechnology;
anti-MMP-14 antibodies were acquired from Millipore;
anti-Sp1 and anti-MDM2 were acquired from Abcam;
anti-myc tag was acquired from Roche; anti-phospho-ERK
1/2 and anti-total ERK antibodies were acquired from
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DNA constructs and dual-luciferase assays

Statistical analysis

Construction of the 1.2 kb MMP-14 promoter
luciferase reporter was performed using a PCR approach
as we have previously described [49, 50]. The PCR
reaction was carried out in the presence of 0.5 M GCrich resolution buffer (Roche) and the PCR products were
then cloned into pGL3 basic vector which contains the
firefly luciferase reporter gene. Truncations, deletions,
and scramble mutations to this construct were generated
using the Q5 Site-Directed Mutagenesis Kit (New England
Biolabs) as previously described [51]. Primers used can
be found in Supplementary Table S1. All constructs were
confirmed by DNA sequencing. To examine promoter
activity, Cos-1 cells were transiently transfected with
the luciferase promoter constructs, p53 or vector control,
and Renilla luciferase reporter gene (1:1:0.5) using
polyethylenimine for 18 hours. 8 hours post-transfection,
firefly and Renilla luciferase activities were measured
using the Dual-Glo Luciferase Assay system (Promega)
as we have previously described [52].

Data are expressed as the mean ± S.E. of triplicates.
Each experiment was repeated at least three times.
Student’s t test was used to assess differences (*p < 0.05;
**p < 0.01; ***p < 0.001).

Chromatin immunoprecipitation (ChIP)

JMC conceived and conducted most of the
experiments, analyzed the results, and wrote most of the
paper. AB and AL conducted in vivo experiments with
JMC. J. Chen and ML provided valuable experimental
insight. J. Cao conceived the idea for the project and
experiments, oversaw the experiments, and wrote the
paper with JMC.

Footnotes
This work is supported in part by National Cancer
Institute (1R01CA166936 to J.C.)
The abbreviations used are: MMP-14, matrix
metalloproteinase-14; IL-6, interleukin-6
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The ChIP assay was performed based on the ZymoSpin ChIP Kit (Zymo Research) using the anti-p53
antibody or the anti-Sp1 antibody. Briefly, cellular
proteins were cross-linked with chromosomal DNA by
1% formaldehyde followed by sonication. Lysates were
immunoprecipitated with the indicated antibody or rabbit
IgG as a control (Millipore) at 4°C overnight in the
presence of protein-A agarose beads. Immunoprecipitated
DNA was amplified by real-time PCR using either
a pair of primers spanning the p53/Sp1 binding site
within the MMP-14 promoter or primers spanning
various regions indicated in Supplementary Table S2.
Immunoprecipitated DNA was calculated according to
the bound (immunoprecipitated chromatin)/input ratio.
Primers used can be found in Supplementary Table S2.
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